The test analyses 31 clinically relevant genes 

Breast and ovarian cancer 

BRCA1, BRCA2, PALB2, CHEK2, RAD51C, and RAD51D

Bowel and gastrointestinal cancer 

APC, MLH1, MSH2, MSH6, PMS2, and MUTYH

Prostate cancer 

HOXB13, ATM, and BRCA2

Pancreatic and kidney cancer 

VHL, STK11, and TP53

Melanoma and skin cancer 

CDKN2A and BAP1

Additional genes within the panel assess broader inherited cancer risk across multiple organ systems.

Genetic cancer risk testing may be considered where there is family history of cancer, particularly where multiple relatives are affected, cancers occur at younger ages, or rare tumour types are present.

It may also be appropriate where personal medical history suggests benefit from further inherited risk assessment.

A negative result means that no clinically significant inherited variants were identified. 

It does not eliminate the possibility of developing cancer in the future. Cancer risk is influenced by many factors beyond inherited genetics so results should always be interpreted within the wider clinical context.

A positive result means a genetic variant has been identified that may increase future cancer risk.

A positive result does NOT indicate current cancer.

This is important as this could influence screening, surveillance, or preventative planning. 

A complimentary consultation with a genetic counsellor is included, providing specialist guidance on the implications of the finding, recommended next steps, and any potential relevance for family members.

No, this test assesses inherited cancer susceptibility rather than diagnosing current disease. 

If there is concern about current cancer risk, further investigations such as a full body MRI or blood-based multi-cancer screening, including Trucheck, may be considered as part of a broader assessment.